Definium Therapeutics, Inc. (DFTX) Stock Forecast Oct. 16, 2026
Analysis updated on Oct. 16, 2026 (UTC) · Total · absolute moveSwitch to Alpha · Nasdaq
Definium Therapeutics, Inc. (DFTX) stock forecast summary
Our AI ranks Definium Therapeutics, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Definium Therapeutics, Inc. is a mid-cap company with a market capitalization of $4.31B. It ranks number 1 by market capitalization among the 29 Medicinal Chemicals & Botanical Products issuers in our coverage with a current forecast.
For DFTX, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 21.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 12.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected absolute price move over the horizon, market included. This is the number a price target is built from. Ratings: strong buy ≥ +5.1%, buy ≥ +3.4%, sell < +1.8%, strong sell < +0.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, DFTX included.
Follow DFTX freeDFTX price chart and AI forecast
How DFTX ranks among 5172 stocks
90D Total forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Definium Therapeutics, Inc. (DFTX) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Medicinal Chemicals & Botanical Products peers listed below that report each metric.
Valuation & Market
| Metric | DFTX | Rank |
|---|---|---|
| Market Cap | $4.31B | 1/29 |
| P/B Ratio | 4.69x | 2/13 |
| EPS | $-3.00 | – |
| Book Value/Share | $6.84 | – |
Profitability & Margins
| Metric | DFTX | Rank |
|---|---|---|
| ROE | -38.5% | 11/16 |
| ROA | -31.8% | 17/25 |
| ROIC | -23.8% | 17/21 |
Financial Health
| Metric | DFTX | Rank |
|---|---|---|
| Current Ratio | 6.95x | 2/29 |
| D/E Ratio | 0.21x | 15/17 |
| Financial Leverage | 1.21x | 15/17 |
| Interest Coverage | -60.9x | 20/22 |
| Working Capital | $935M | 1/29 |
Cash Flow
| Metric | DFTX | Rank |
|---|---|---|
| Operating Cash Flow | -$168M | 29/30 |
Income Statement
| Metric | DFTX | Rank |
|---|---|---|
| Operating Income | -$228M | 25/28 |
| Net Income | -$354M | 23/25 |
| R&D Expense | $155M | 1/9 |
Dividend & Shareholder Information
| Metric | DFTX | Rank |
|---|---|---|
| Shares Outstanding | 134M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $1.09B | 98.0% of assets |
| Cash & Short-term Investments | $655M | 58.8% of assets |
| Total Liabilities | $194M | 17.4% of assets |
| Short-term Debt | $150M | 13.5% of assets |
DFTX quarterly financials and insider trading
Definium Therapeutics, Inc. (DFTX) industry peers
Companies classified under the same SEC industry code as Definium Therapeutics, Inc. (Medicinal Chemicals & Botanical Products): 33 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Total) | Market Cap |
|---|---|---|
| DFTX Definium Therapeutics, Inc. | ▲ | $4.31B |
| TRLV Trulieve Cannabis Corp. | ▶ | $1.93B |
| CRON Cronos Group Inc. | ▶ | $1.18B |
| TLRY Tilray Brands, Inc. | ▶ | $414M |
| SNDL Sndl Inc. | ▶ | $322M |
| CGC Canopy Growth Corp | ▶ | $302M |
| GLAS Glass House Brands Inc. | ▼ | $301M |
| USNA Usana Health Sciences Inc | ▼ | $287M |
| ACB Aurora Cannabis Inc | ▶ | $253M |
| NAGE Niagen Bioscience, Inc. | ▶ | $197M |
| MDWD Mediwound Ltd. | ▶ | $152M |
| AAWH Ascend Wellness Holdings, Inc. | ▲ | $80M |
| FTLF Fitlife Brands, Inc. | ▶ | $79M |
| BTMD Biote Corp. | ▲ | $35M |
| RAPH Raphael Pharmaceutical Inc. | ▼ | $30M |
| CHUC Charlie's Holdings, Inc. | ▶ | $27M |
| MRMD Marimed Inc. | ▲ | $24M |
| CFOO China Foods Holdings Ltd. | ▼ | $21M |
| MTEX Mannatech Inc | ▲ | $14M |
| ADIA Adia Med, Inc. | ▲ | $13M |
| GLUC Glucose Health, Inc. | ▼ | $9M |
| NAII Natural Alternatives International Inc | ▲ | $7M |
| BON Bon Natural Life Ltd | ▼ | $7M |
| PLSH Panacea Life Sciences Holdings, Inc. | ▲ | $6M |
| CYAN Cyanotech Corp | ▲ | $5M |
| IMCC Im Cannabis Corp. | ▼ | $2M |
| AIBT Aibotics, Inc. | ▼ | $2M |
| NPHC Nutra Pharma Corp | ▼ | $720K |
| MEHA Functional Brands Inc. | ▼ | $290K |
| CBDY Target Group Inc. | ▼ | N/A |
| HYEX Healthy Extracts Inc. | ▲ | N/A |
| NTRR Neutra Corp. | ▼ | N/A |
| SNYRQ Synergy Chc Corp. | ▼ | N/A |
Where DFTX sits on the market map
Definium Therapeutics, Inc. (DFTX) stock news
Loading...
Definium Therapeutics, Inc. (DFTX) stock forecast FAQ
What is the Definium Therapeutics, Inc. (DFTX) stock forecast?
Our AI ranks Definium Therapeutics, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
How accurate are Definium Therapeutics, Inc. stock predictions?
For DFTX, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 21.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 12.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Definium Therapeutics, Inc. forecasts updated?
Definium Therapeutics, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.
Which companies are Definium Therapeutics, Inc.'s industry peers?
33 issuers in our coverage, DFTX included, share the SEC industry code Medicinal Chemicals & Botanical Products. The largest are: Trulieve Cannabis Corp. (TRLV), Cronos Group Inc. (CRON), Tilray Brands, Inc. (TLRY), Sndl Inc. (SNDL), Canopy Growth Corp (CGC), Glass House Brands Inc. (GLAS).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.